Kira Pharmaceuticals is developing a new generation of complement-targeted therapies to treat immune-mediated and complement-driven diseases. Its efforts are enabled by the LOGIC drug discovery platform. The company is committed to advancing first-in-class and best-in-class therapies to transform patients' lives. Kira announced $46M in investments secured to date. It is backed by a syndicate of global life science venture firms including Quan Capital, 6 Dimensions Capital, Qiming Venture Partners, and Sinopharm Capital. Frederick Beddingfield, MD, PhD, was appointed Chief Executive Officer.

Total raised

$46M

Funding rounds

1

Latest round

Equity

Latest activity

Nov 2020